Jakarta, The Indonesia Post – Indonesian President Joko Widodo has given names to two domestically made COVID-19 vaccine products that are currently entering the final phase of clinical trials, said an official from the Indonesian Food and Drug Administration (BPOM).
“I am proud of Indonesia. Indovac’s first vaccine is for state owned enterprises (BUMN) vaccines, and the second is the Red and White Vaccine with an inactivated virus platform, the name is Inavac and has been approved by the President,” said the Head of BPOM RI Penny K Lukito in the agenda of the Domestic Drug Development Workshop at the Hotel Ayana MidPlaza Jakarta, Friday.
Penny said the Indovac vaccine with a sub-unit recombinant protein platform was developed by the Eijkman Institute for Molecular Biology together with PT Bio Farma and Baylor College of Medicine.
Meanwhile, the Inavac vaccine with an inactivated virus platform was developed by a research team from Universitas Airlangga (Unair) in collaboration with production facility provider PT Biotis Pharmaceutical Indonesia.
Penny targets the Indovac and Inavac vaccines to obtain an emergency use permit (EUA) from the Indonesian National Food and Drug Administration (BPOM) in September 2022.
“Phase two has been passed, and the results are good, it can improve the immune system and the results are not inferior to vaccines that have received EUA with the same technology,” he said.
Currently, BPOM is still reviewing research reports on thousands of subjects who underwent a second injection in each trial laboratory.
“Hopefully, in September 2022, the EUA will be completed and the EUA will come out according to international standards,” he said.
The third phase of clinical trials of the two domestic vaccines is also accompanied by the granting of permits for clinical trial activities for booster vaccines or booster doses.
“The booster clinical trial has been approved to be carried out at the end of this year. So the booster vaccination program with domestic vaccines can be completed before the end of the year,” he said.
On the same agenda, President Director of PT Biotis Pharmaceutical Indonesia, FX Sudirman, was proud of vaccines with the development of domestic vaccines that have reached the final phase of clinical trials.
“This is 100 percent the work of the nation’s children, the virus from the isolation of the nation’s children was developed by the Unair research team and we are ready to commercialize it,” he said.
The downstream production capacity of PT Biotis is capable of producing up to 20 million doses per month. Especially in the early stages, it will be increased to 5 million doses per month similar to Indovac,” he said.
Until now, PT Biotis is still waiting for the results of phase three clinical trials and booster clinical trials. “We hope that the use of Inavac can provide booster benefits for the people of Indonesia this year,” he said.
FX Sudirman has coordinated with the Indonesian Minister of Health Budi Gunadi Sadikin so that the implementation of the Inavac booster vaccine can be rolled out in October, November and December 2022. (mhn/bbs)
Comment